Today's Trend
The Chemours Company (NYSE: CC) is under pressure today after a wave of analyst updates pointed to softer near-term earnings expectations. Zacks Research trimmed estimates for FY2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q1 2028, and FY2028, suggesting slower profitability in the next few years. The biggest near-term cut was for Q2 2026 EPS, which was reduced from $0.60 to $0.33, a notably more cautious view that can weigh on the stock.
Offsetting some of that negative sentiment, JPMorgan raised its price target on Chemours to $22 from $17 while keeping a neutral rating. That implies only modest upside from the current share price, so it is more of a valuation reset than a strong bullish call.
- JPMorgan increased its price target to $22 from $17, signaling slightly improved valuation expectations for Chemours (NYSE: CC). Benzinga
- JPMorgan maintained a neutral rating, indicating limited conviction that the shares will outperform from here. Tickerreport.com
- Zacks Research sharply lowered Q2 2026 EPS estimates to $0.33 from $0.60, pointing to weaker near-term earnings momentum. MarketBeat CC
- Additional downward revisions to FY2026 and several 2027/2028 earnings estimates reinforce concerns that Chemours' profit recovery may take longer than expected. MarketBeat CC
Overall, CC is moving lower as investors focus more on the analyst earnings cuts than on the slightly higher price target.